TriSalus Life Sciences Inc (NAS:TLSI)

Q2 2025 TriSalus Life Sciences Inc Earnings Call Transcript

Aug 12, 2025 / 08:30 PM GMT

Release Date Price: $3.65 (+2.24%)

Transcript 10-Q8-K

Key Points

Positve

TriSalus Life Sciences Inc (TLSI) reported strong Q2 2025 results with net sales of $11.2 million, marking a 52% increase compared to Q2 2024 and a 22% sequential gain over Q1 2025.
The company successfully launched the TriNav Flex infusion system and completed a $22 million private placement with healthcare-focused institutional investors.
TriSalus expanded its market opportunity and simplified its capital structure through the successful completion of an exchange offer and consent solicitation for preferred stock.
The Centers for Medicare and Medicaid Services issued a new code for TriNav, doubling the reimbursable use of the technology and supporting broader adoption.
Initial sales of the newly launched TriNav Flex are exceeding internal projections, contributing to commercial momentum.

Negative

Gross margin declined to 84% from 88% in Q2 2024, primarily due to lower manufacturing efficiency associated with newly launched products.
Research and development expenses were $3.9 million, with approximately $500,000 of non-recurring expenses related to the Nelatolamod clinical trial closeout.
Sales and marketing expenses increased to $7.2 million from $6 million in Q2 2024, reflecting investments in expanding the commercial organization.
General and administrative expenses rose to $5.7 million from $4 million in Q2 2024, driven by non-recurring legal and audit professional service expenses.
The company anticipates delaying EBITDA positivity or cash flow positivity until 2026 due to strategic investments in business expansion.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

TLSI.OQ - TriSalus Life Sciences Inc
Q2 2025 TriSalus Life Sciences Inc Earnings Call
Aug 12, 2025 / 08:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good afternoon and welcome to Trielass Life Sciences 2nd quarter 2025 earnings conference call. Currently all participants are in a listen-only mode.

Following management prepared remarks, we will hold the question and answer session. As a reminder, this call is being recorded for replay purposes. I will now attend the call over to Jeremy Feffer, managing director with Life Sci-fi advisor. Please go ahead, sir.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Thank you, operator, and thank you all for participating in today's call. Joining me today from Trialus

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.